Top 5 Restaurants VC (Venture Capital) Funds in Switzerland in January 2026

Last updated: Jan 2026 A list of 5 VC (Venture Capital) funds that invest in Restaurants startups based in Switzerland. We rank investors based on the number of investments they made in Restaurants companies from Switzerland. We update this investor list every month.

Top 5 Restaurants VC (Venture Capital) Funds in Switzerland in January 2026

Investor	Restaurants Switzerland investments
3wVentures	2
4See Ventures	1
Prediction Capital	1
Innosuisse	1
Verve Ventures	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

3wVentures provides seed money and venture capital to international internet startups. As they focus on early stage projects and prototypes, our investments and co-investments target a volume of up to USD 250,000.

Investment focus

Software, Health Care, Information Technology
Seed, Angel, Series A
Switzerland, Spain, Austria

Portfolio highlights

Abionic — Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from:
GUURU — GUURU is a Customer Interaction Solution that combines AI with the human experience of product users. We enable brands to provide efficient First Contact Resolution with a single platform leveraging their most proficient and dedicated customers. Contact us to find out more.
Pregnolia — Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete theclinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.

4see ventures is a Swiss venture capital firm investing in exceptional entrepreneurs who are defining the future. We focus on real game-changers in their industries who are having a positive impact on society.

Investment focus

Medical, Health Care, Security
Seed, Series C
Switzerland, Israel

Portfolio highlights

CYSEC — Secure your sensitive data in the cloud and in the edge with ARCA Trusted OS and open the door to innovation with confidential computing.
PowerAPI — Foodetective enables F&B businesses to integrate & manage their entire tech stack from a single OS & platform. Increasing online revenues and visibility as well as removing all operational & administrative tasks. Our vision is to become the intelligent OS & interface of the F&B industry.
HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.

Prediction Capital is an early-stage ConsumerTech and FinTech investment firm. We are a young and dynamic team, acting eye-to-eye with our founders.

Investment focus

Software, SaaS, EdTech
Seed, Pre-Seed
Germany, Switzerland

Portfolio highlights

PowerAPI — Foodetective enables F&B businesses to integrate & manage their entire tech stack from a single OS & platform. Increasing online revenues and visibility as well as removing all operational & administrative tasks. Our vision is to become the intelligent OS & interface of the F&B industry.
Bling.de — The pocket money card and app that empowers children & teens to be money-smart. Safe, simple and educational.
info.link — House of Change is building the Sustainability Copilot to democratise sustainability expertise. Get on the waitlist for the best AI in sustainability.

Innosuisse’s role is to promote science-based innovation in the interests of industry and society in Switzerland.

Investment focus

Health Care, Biotechnology, Medical Device
Grant, Pre-Seed, Seed
Switzerland, United States, United Kingdom

Portfolio highlights

Hemetron — Over 100 million people globally suffer from Inflammatory Rheumatic Diseases (IRD), causing chronic pain, fatigue, and flare-ups that significantly reduce quality of life. Traditional monitoring, with doctor visits every 3-6 months, leaves gaps in tracking disease progression, leading to poor outcomes and suffering. Hemetron AG addresses thisproblem with a groundbreaking remote monitoring system, enabling patients to conduct at-home blood tests. Results are digitally sent to physicians for timely treatment adjustments. This solution improves disease tracking, patient engagement, and reduces costs. We revolutionize chronic patient care through more personalized and effective treatments, delivering better outcomes at lower costs.
HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.